vs
Azenta, Inc.（AZTA）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
Azenta, Inc.的季度营收约是PUMA BIOTECHNOLOGY, INC.的2.0倍（$148.6M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 0.8%），Azenta, Inc.自由现金流更多（$14.7M vs $14.4M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 4.4%）
Azenta成立于1978年，总部位于美国马萨诸塞州切姆斯福德，是全球知名的生命科学服务提供商，核心业务覆盖基因组学、低温存储、自动化解决方案及信息学服务，为生命科学领域研究及产业客户提供专业技术支持。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
AZTA vs PBYI — 直观对比
营收规模更大
AZTA
是对方的2.0倍
$75.5M
营收增速更快
PBYI
高出27.0%
0.8%
自由现金流更多
AZTA
多$272.0K
$14.4M
两年增速更快
PBYI
近两年复合增速
4.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $148.6M | $75.5M |
| 净利润 | $-15.4M | — |
| 毛利率 | 42.9% | 69.3% |
| 营业利润率 | -4.9% | 22.7% |
| 净利率 | -10.4% | — |
| 营收同比 | 0.8% | 27.7% |
| 净利润同比 | -15.7% | — |
| 每股收益（稀释后） | $-0.34 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AZTAPBYI
| Q4 25 | $148.6M | $75.5M | ||
| Q3 25 | $159.2M | $54.5M | ||
| Q2 25 | $143.9M | $52.4M | ||
| Q1 25 | $143.3M | $46.0M | ||
| Q4 24 | $147.4M | $59.1M | ||
| Q3 24 | $150.6M | $80.5M | ||
| Q2 24 | $144.3M | $47.1M | ||
| Q1 24 | $136.4M | $43.8M |
净利润AZTAPBYI
| Q4 25 | $-15.4M | — | ||
| Q3 25 | $50.9M | $8.8M | ||
| Q2 25 | $-48.0M | $5.9M | ||
| Q1 25 | $-47.7M | $3.0M | ||
| Q4 24 | $-11.0M | — | ||
| Q3 24 | $-6.6M | $20.3M | ||
| Q2 24 | $-6.6M | $-4.5M | ||
| Q1 24 | $-137.4M | $-4.8M |
毛利率AZTAPBYI
| Q4 25 | 42.9% | 69.3% | ||
| Q3 25 | 45.4% | 77.7% | ||
| Q2 25 | 46.2% | 76.5% | ||
| Q1 25 | 43.8% | 77.1% | ||
| Q4 24 | 46.7% | 76.4% | ||
| Q3 24 | 45.5% | 63.9% | ||
| Q2 24 | 44.8% | 77.4% | ||
| Q1 24 | 43.8% | 75.5% |
营业利润率AZTAPBYI
| Q4 25 | -4.9% | 22.7% | ||
| Q3 25 | 1.2% | 17.6% | ||
| Q2 25 | -1.3% | 12.7% | ||
| Q1 25 | -12.7% | 8.7% | ||
| Q4 24 | -5.9% | 22.6% | ||
| Q3 24 | -3.1% | 27.4% | ||
| Q2 24 | -4.9% | -4.6% | ||
| Q1 24 | -18.1% | -5.3% |
净利率AZTAPBYI
| Q4 25 | -10.4% | — | ||
| Q3 25 | 32.0% | 16.2% | ||
| Q2 25 | -33.4% | 11.2% | ||
| Q1 25 | -33.3% | 6.5% | ||
| Q4 24 | -7.5% | — | ||
| Q3 24 | -4.4% | 25.2% | ||
| Q2 24 | -4.5% | -9.6% | ||
| Q1 24 | -100.8% | -11.0% |
每股收益（稀释后）AZTAPBYI
| Q4 25 | $-0.34 | $0.26 | ||
| Q3 25 | $1.12 | $0.17 | ||
| Q2 25 | $-1.05 | $0.12 | ||
| Q1 25 | $-1.04 | $0.06 | ||
| Q4 24 | $-0.25 | $0.40 | ||
| Q3 24 | $-0.25 | $0.41 | ||
| Q2 24 | $-0.12 | $-0.09 | ||
| Q1 24 | $-2.48 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $336.6M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $1.7B | $130.3M |
| 总资产 | $2.1B | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资AZTAPBYI
| Q4 25 | $336.6M | $97.5M | ||
| Q3 25 | $279.8M | $94.4M | ||
| Q2 25 | $270.0M | $96.0M | ||
| Q1 25 | $253.6M | $93.2M | ||
| Q4 24 | $377.5M | $101.0M | ||
| Q3 24 | $280.0M | $96.7M | ||
| Q2 24 | $336.5M | $96.8M | ||
| Q1 24 | $353.5M | $107.2M |
总债务AZTAPBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益AZTAPBYI
| Q4 25 | $1.7B | $130.3M | ||
| Q3 25 | $1.7B | $115.3M | ||
| Q2 25 | $1.7B | $104.7M | ||
| Q1 25 | $1.7B | $97.1M | ||
| Q4 24 | $1.7B | $92.1M | ||
| Q3 24 | $1.8B | $71.1M | ||
| Q2 24 | $2.0B | $48.5M | ||
| Q1 24 | $2.2B | $51.0M |
总资产AZTAPBYI
| Q4 25 | $2.1B | $216.3M | ||
| Q3 25 | $2.1B | $202.9M | ||
| Q2 25 | $2.0B | $194.9M | ||
| Q1 25 | $2.0B | $196.2M | ||
| Q4 24 | $2.0B | $213.3M | ||
| Q3 24 | $2.1B | $220.7M | ||
| Q2 24 | $2.3B | $205.0M | ||
| Q1 24 | $2.6B | $214.1M |
负债/权益比AZTAPBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $20.8M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $14.7M | $14.4M |
| 自由现金流率自由现金流/营收 | 9.9% | 19.1% |
| 资本支出强度资本支出/营收 | 4.2% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $30.9M | $41.7M |
8季度趋势，按日历期对齐
经营现金流AZTAPBYI
| Q4 25 | $20.8M | $14.4M | ||
| Q3 25 | $2.2M | $9.7M | ||
| Q2 25 | $25.8M | $14.1M | ||
| Q1 25 | $14.4M | $3.6M | ||
| Q4 24 | $29.8M | $15.6M | ||
| Q3 24 | $17.7M | $11.0M | ||
| Q2 24 | $9.8M | $1.0M | ||
| Q1 24 | $8.7M | $11.2M |
自由现金流AZTAPBYI
| Q4 25 | $14.7M | $14.4M | ||
| Q3 25 | $-5.7M | $9.7M | ||
| Q2 25 | $15.0M | $14.1M | ||
| Q1 25 | $7.0M | $3.6M | ||
| Q4 24 | $22.0M | $15.6M | ||
| Q3 24 | $8.3M | $11.0M | ||
| Q2 24 | $1.3M | $1.0M | ||
| Q1 24 | $428.0K | — |
自由现金流率AZTAPBYI
| Q4 25 | 9.9% | 19.1% | ||
| Q3 25 | -3.6% | 17.7% | ||
| Q2 25 | 10.4% | 26.8% | ||
| Q1 25 | 4.9% | 7.7% | ||
| Q4 24 | 15.0% | 26.4% | ||
| Q3 24 | 5.5% | 13.7% | ||
| Q2 24 | 0.9% | 2.1% | ||
| Q1 24 | 0.3% | — |
资本支出强度AZTAPBYI
| Q4 25 | 4.2% | 0.0% | ||
| Q3 25 | 4.9% | 0.0% | ||
| Q2 25 | 7.5% | 0.0% | ||
| Q1 25 | 5.2% | 0.1% | ||
| Q4 24 | 5.3% | 0.0% | ||
| Q3 24 | 6.2% | 0.0% | ||
| Q2 24 | 5.9% | 0.0% | ||
| Q1 24 | 6.1% | 0.0% |
现金转化率AZTAPBYI
| Q4 25 | — | — | ||
| Q3 25 | 0.04× | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AZTA
| Multiomics | $67.2M | 45% |
| Core Products | $47.6M | 32% |
| Sample Repository Solutions | $33.8M | 23% |
PBYI
暂无分部数据
